Discordance of human epidermal growth factor receptor 2‐low status between breast primary and distant metastases with clinical–pathological correlation
Histopathology · 2025-02 · 86 (3) · 441-449
DOI: 10.1111/his.15346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 17.10.2024. Verfasst von Ellen Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor, Breast Neoplasms, Immunohistochemistry. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Aims
Breast cancer with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 1+ or 2+ with negative in‐situ hybridisation (ISH) (HER2‐low) can now be targeted by HER2 antibody drug conjugates. We set out to compare HER2 status between matched primary invasive breast carcinoma (IBC) and distant metastases (DM) with clinical–pathological correlation, with specific interest in HER2‐low.
Methods
Biomarker studies and clinical–pathological features of primary IBC with matched DM diagnosed between 2021 and 2022 were retrospectively analysed. HER2 status was assessed per 2023 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines for IHC (4B5) and ISH (IQFISH pharmDX). Bilateral breast primaries were excluded. HER2 IHC 0 to 1+ were reassessed.
Results
One hundred and forty‐seven cases of primary IBC with matched DM were identified. Biomarkers were performed on core biopsy ( n = 74) and resection ( n = 73). One hundred and twenty‐six (86%) were initially classified as ‘HER2‐negative’; of these, 67 (46%) were reclassified as HER2‐low. Patients with HER2‐positive primaries were younger ( P = 0.01) and had an increased incidence of micropapillary carcinoma ( P = 0.02). HER2‐low primaries also had an increased incidence of micropapillary carcinoma ( P = 0.02) and oestrogen receptor (ER) positivity ( P = 0.02) compared to HER2 0. One hundred and sixty‐nine matched DM cases excluding bone metastasis were identified (range = one to seven metastases per IBC). The most common sites of metastases were liver (50 of 169, 30%), lung (36 of 169; 21%), distant lymph node (26 of 169, 15%); 138 DM cases (82%) were previously classified as ‘HER2‐negative’, and 62 (37%) were reclassified as HER2‐low. Like HER2‐low primaries, HER2‐low metastases were frequently ER‐positive (52 of 62; 84%) ( P = 0.02). Brain metastases were more frequently HER2‐positive (five of 32; 16%) ( P = 0.04). Comparing HER2 status in matched primaries and DM, HER2 status was discordant in 62 cases (37%). Most changes occurred from HER2‐low to HER2 0 (33 of 169, 20%), HER2 0 to HER2‐low (17 of 169, 10%) and HER2‐low to positive (10 of 169, 6%). All HER2‐low to HER2 0 changes were HER2 1+ to 0. In 30 patients with multiple DM sites (47 cases), HER2 status among different DM samples was discordant in 16 patients (53%), mainly from HER2‐low to HER2 0 (16 of 47, 34%).
Conclusion
A significant proportion of previous ‘HER2‐negative’ primaries and DM cases were reclassified as HER2‐low. Discordant HER2 status between IBC primary and metastasis and between different DM sites demonstrated tumour heterogeneity and highlights the need for HER2 retesting in distant metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
- Department of Pathology, North Shore University Hospital, Northwell Health, Manhasset, NY, USA.
- Department of Surgey, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Ellen Yang, Timothy M D'Alfonso, Monica Morrow, Edi Brogi, Hannah Y Wen
Zitieren
APA
Yang, E., D'Alfonso, T. M., Morrow, M., Brogi, E., & Wen, H. Y. (2025). Discordance of human epidermal growth factor receptor 2‐low status between breast primary and distant metastases with clinical–pathological correlation. Histopathology, 86(3), 441-449. https://doi.org/10.1111/his.15346
Vancouver
Yang E, D'Alfonso TM, Morrow M, Brogi E, Wen HY. Discordance of human epidermal growth factor receptor 2‐low status between breast primary and distant metastases with clinical–pathological correlation. Histopathology. 2025;86(3):441-449. doi:10.1111/his.15346
BibTeX
@article{Yang2025,
author = {Yang, Ellen and D'Alfonso, Timothy M and Morrow, Monica and Brogi, Edi and Wen, Hannah Y},
title = {Discordance of human epidermal growth factor receptor 2‐low status between breast primary and distant metastases with clinical–pathological correlation},
journal = {Histopathology},
year = {2025},
volume = {86},
number = {3},
pages = {441--449},
doi = {10.1111/his.15346}
}
EUVIMED